Istaroxime

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Istaroxime
Accession Number
DB06157
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • ST-2744
External IDs
PST-2744
Product Ingredients
IngredientUNIICASInChI Key
Istaroxime HydrochlorideN24U08609A374559-48-5AXHJYJDJXNOGNI-DESZRGPQSA-N
Categories
UNII
W8I9H2TPPL
CAS number
203737-93-3
Weight
Average: 360.498
Monoisotopic: 360.241292898
Chemical Formula
C21H32N2O3
InChI Key
MPYLDWFDPHRTEG-IFVNMTGRSA-N
InChI
InChI=1S/C21H32N2O3/c1-20-7-5-13(23-26-10-9-22)11-17(20)18(24)12-14-15-3-4-19(25)21(15,2)8-6-16(14)20/h14-17H,3-12,22H2,1-2H3/t14-,15-,16-,17+,20+,21-/m0/s1
IUPAC Name
(1S,2R,7S,10R,11S,15S)-5-[(2-aminoethoxy)imino]-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecane-8,14-dione
SMILES
C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4CC(CC[C@]34C)=NOCCN)[C@@H]1CCC2=O

Pharmacology

Indication

Investigated for use/treatment in heart disease.

Pharmacodynamics
Not Available
Mechanism of action

Reduces the sodium-potassium adenosine triphosphatase (ATPase) activity and stimulates the sarcoplasmic calcium ATPase isoform 2 reuptake function.

TargetActionsOrganism
USarcoplasmic/endoplasmic reticulum calcium ATPase 2Not AvailableHuman
USodium/potassium-transporting ATPase subunit alpha-1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Istaroxime.Investigational
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Istaroxime is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Istaroxime.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Istaroxime.Approved, Experimental, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Istaroxime is combined with Acetaminophen.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Istaroxime.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Istaroxime.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Istaroxime.Approved, Withdrawn
AldesleukinIstaroxime may decrease the antineoplastic activities of Aldesleukin.Approved
AlmasilateThe bioavailability of Istaroxime can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Istaroxime.Experimental
AloglutamolThe bioavailability of Istaroxime can be decreased when combined with Aloglutamol.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Istaroxime.Experimental
AluminiumThe bioavailability of Istaroxime can be decreased when combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe bioavailability of Istaroxime can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Istaroxime can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Istaroxime can be decreased when combined with Aluminum hydroxide.Approved, Investigational
AmbenoniumThe risk or severity of adverse effects can be increased when Istaroxime is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Istaroxime.Approved
AmiodaroneThe serum concentration of Istaroxime can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BIstaroxime may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Istaroxime.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Istaroxime.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Istaroxime is combined with Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Istaroxime.Approved, Investigational
AntrafenineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Istaroxime can be decreased when it is combined with Apalutamide.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Istaroxime.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Istaroxime.Approved, Investigational
AprepitantThe serum concentration of Istaroxime can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Istaroxime can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Istaroxime.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Istaroxime.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Istaroxime.Approved
AzosemideIstaroxime may increase the hypokalemic activities of Azosemide.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Istaroxime is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Istaroxime is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Istaroxime.Approved, Investigational
BazedoxifeneThe serum concentration of Istaroxime can be increased when it is combined with Bazedoxifene.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Istaroxime is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Istaroxime.Experimental
BendroflumethiazideIstaroxime may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Istaroxime.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Istaroxime.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Istaroxime.Approved, Investigational
BenzthiazideIstaroxime may increase the hypokalemic activities of Benzthiazide.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Istaroxime.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Istaroxime.Experimental
Bismuth subcitrate potassiumThe bioavailability of Istaroxime can be decreased when combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateThe bioavailability of Istaroxime can be decreased when combined with Bismuth subnitrate.Approved
BoceprevirThe serum concentration of Istaroxime can be increased when it is combined with Boceprevir.Approved, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Istaroxime.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Istaroxime.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Istaroxime.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Istaroxime.Experimental
BumetanideIstaroxime may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Istaroxime.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Istaroxime can be decreased when combined with Calcium Carbonate.Approved, Investigational
Calcium silicateThe bioavailability of Istaroxime can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideIstaroxime may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CapsaicinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Capsaicin.Approved
CarbamazepineThe serum concentration of Istaroxime can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Istaroxime.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Istaroxime.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Istaroxime.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Istaroxime.Approved, Investigational
CeritinibIstaroxime may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Istaroxime.Approved, Investigational, Vet Approved
ChlorothiazideIstaroxime may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Istaroxime can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneIstaroxime may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Istaroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Istaroxime.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Istaroxime is combined with Cimicoxib.Investigational
CinoxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Cisplatin.Approved
ClarithromycinThe serum concentration of Istaroxime can be increased when it is combined with Clarithromycin.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Istaroxime is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Istaroxime.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Istaroxime is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Istaroxime can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Istaroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Istaroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Istaroxime can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Istaroxime.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Istaroxime is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Istaroxime is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Istaroxime.Approved, Investigational
CyclopenthiazideIstaroxime may increase the hypokalemic activities of Cyclopenthiazide.Experimental
DaidzeinThe serum concentration of Istaroxime can be increased when it is combined with Daidzein.Experimental
DanazolIstaroxime may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of Istaroxime can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Istaroxime is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Istaroxime is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Istaroxime is combined with Demecarium.Approved
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Istaroxime.Investigational
DexibuprofenThe risk or severity of adverse effects can be increased when Istaroxime is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Istaroxime is combined with Dexketoprofen.Approved, Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Istaroxime is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Istaroxime.Approved, Vet Approved
DienestrolThe serum concentration of Istaroxime can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Istaroxime can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Istaroxime.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Istaroxime.Approved, Investigational
DipivefrinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Dipivefrin.Approved
DistigmineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Istaroxime is combined with Donepezil.Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Istaroxime is combined with Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Istaroxime.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Istaroxime.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Istaroxime.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Istaroxime is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Istaroxime is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Istaroxime can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Istaroxime can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Istaroxime.Approved
EpitizideIstaroxime may increase the hypokalemic activities of Epitizide.Experimental
EquolThe serum concentration of Istaroxime can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Istaroxime can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Istaroxime can be increased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Istaroxime can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Istaroxime can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Istaroxime can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Istaroxime can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Istaroxime can be increased when it is combined with Estrone.Approved
Etacrynic acidIstaroxime may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Istaroxime.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Istaroxime.Experimental
Ethinyl EstradiolThe serum concentration of Istaroxime can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Istaroxime.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Istaroxime.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Istaroxime.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Istaroxime.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Istaroxime.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Istaroxime.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Istaroxime.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Istaroxime.Approved
FenthionThe risk or severity of adverse effects can be increased when Istaroxime is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Istaroxime.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Istaroxime.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Istaroxime.Experimental
Fish oilThe risk or severity of adverse effects can be increased when Istaroxime is combined with Fish oil.Approved, Nutraceutical
FleroxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Istaroxime.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Istaroxime.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Istaroxime.Experimental
FluoxymesteroneIstaroxime may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Istaroxime.Approved, Investigational
FosaprepitantThe serum concentration of Istaroxime can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Istaroxime can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FurosemideIstaroxime may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Istaroxime is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Istaroxime is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Istaroxime can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Istaroxime is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Istaroxime is combined with Ginkgo biloba.Approved, Investigational, Nutraceutical
GinsengThe risk or severity of adverse effects can be increased when Istaroxime is combined with Ginseng.Approved, Investigational, Nutraceutical
GLPG-0492Istaroxime may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Istaroxime.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Istaroxime.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Istaroxime.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Istaroxime is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Istaroxime can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Istaroxime.Investigational
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Human rabies virus immune globulin.Approved
Huperzine AThe risk or severity of adverse effects can be increased when Istaroxime is combined with Huperzine A.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Istaroxime.Approved, Investigational
HydrochlorothiazideIstaroxime may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideIstaroxime may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Istaroxime can be decreased when combined with Hydrotalcite.Approved, Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Istaroxime.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Istaroxime.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Istaroxime.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Istaroxime is combined with Icosapent.Approved, Nutraceutical
IdelalisibThe serum concentration of Istaroxime can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Istaroxime.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Istaroxime.Approved
IndapamideIstaroxime may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Istaroxime can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Istaroxime.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Istaroxime.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Istaroxime.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Istaroxime is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Istaroxime is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Istaroxime is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Istaroxime.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Istaroxime.Withdrawn
ItraconazoleThe serum concentration of Istaroxime can be increased when it is combined with Itraconazole.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Istaroxime is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Istaroxime.Experimental
KetoconazoleThe serum concentration of Istaroxime can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Istaroxime.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Istaroxime.Approved
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Istaroxime.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Istaroxime.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Istaroxime.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Istaroxime.Experimental
LopinavirThe serum concentration of Istaroxime can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Istaroxime.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Istaroxime.Approved, Investigational
LumacaftorThe serum concentration of Istaroxime can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Istaroxime.Approved, Investigational
MagaldrateThe bioavailability of Istaroxime can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium carbonateThe bioavailability of Istaroxime can be decreased when combined with Magnesium carbonate.Approved, Investigational
Magnesium hydroxideThe bioavailability of Istaroxime can be decreased when combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe bioavailability of Istaroxime can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Istaroxime can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Istaroxime.Approved
Magnesium silicateThe bioavailability of Istaroxime can be decreased when combined with Magnesium silicate.Approved
Magnesium TrisilicateThe bioavailability of Istaroxime can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Istaroxime is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Istaroxime.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Istaroxime.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Istaroxime.Approved
MefloquineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Mefloquine.Approved, Investigational
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Istaroxime.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Istaroxime.Approved
MesteroloneIstaroxime may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Istaroxime can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Istaroxime.Approved, Investigational, Withdrawn
MethallenestrilThe serum concentration of Istaroxime can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Istaroxime is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideIstaroxime may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Istaroxime.Approved, Vet Approved
MethyltestosteroneIstaroxime may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Istaroxime is combined with Metoclopramide.Approved, Investigational
MetolazoneIstaroxime may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Istaroxime can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Minaprine.Approved
MitotaneThe serum concentration of Istaroxime can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Istaroxime.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Istaroxime.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Istaroxime.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Istaroxime is combined with Morniflumate.Approved
MoxestrolThe serum concentration of Istaroxime can be increased when it is combined with Moxestrol.Experimental
MoxifloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Istaroxime.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Istaroxime.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Istaroxime.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Istaroxime.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Istaroxime.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Istaroxime is combined with Nalidixic Acid.Approved, Investigational
NandroloneIstaroxime may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateIstaroxime may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Istaroxime.Approved, Vet Approved
NefazodoneThe serum concentration of Istaroxime can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Istaroxime can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Istaroxime.Approved, Investigational
NevirapineThe serum concentration of Istaroxime can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Istaroxime is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Istaroxime.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Istaroxime.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Istaroxime.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Istaroxime.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Istaroxime.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Istaroxime.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Istaroxime.Vet Approved
OxandroloneIstaroxime may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Istaroxime.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Istaroxime is combined with Oxolinic acid.Experimental
OxymetholoneIstaroxime may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Istaroxime.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Istaroxime.Experimental, Nutraceutical
ParaoxonThe risk or severity of adverse effects can be increased when Istaroxime is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Istaroxime.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Istaroxime.Approved, Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Istaroxime can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenobarbitalThe serum concentration of Istaroxime can be decreased when it is combined with Phenobarbital.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Istaroxime.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Istaroxime.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Istaroxime.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Istaroxime.Approved, Investigational
PhenytoinThe serum concentration of Istaroxime can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Physostigmine.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Istaroxime.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Istaroxime is combined with Pipemidic acid.Experimental
PiretanideIstaroxime may increase the hypokalemic activities of Piretanide.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Istaroxime.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Istaroxime is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Istaroxime.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Istaroxime.Experimental
Polyestradiol phosphateThe serum concentration of Istaroxime can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideIstaroxime may increase the hypokalemic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Istaroxime is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Istaroxime can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Istaroxime.Experimental, Investigational
PrimidoneThe serum concentration of Istaroxime can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Istaroxime.Experimental
PromestrieneThe serum concentration of Istaroxime can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Istaroxime.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Istaroxime.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Istaroxime.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Istaroxime.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Pyridostigmine.Approved, Investigational
QuinestrolThe serum concentration of Istaroxime can be increased when it is combined with Quinestrol.Approved
QuinethazoneIstaroxime may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Istaroxime is combined with Rabies virus inactivated antigen, A.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Istaroxime.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Istaroxime.Approved, Experimental, Investigational
RifabutinThe serum concentration of Istaroxime can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Istaroxime can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Istaroxime can be decreased when it is combined with Rifapentine.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Istaroxime is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Istaroxime.Approved, Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Rubella virus vaccine.Approved, Investigational
RufloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Istaroxime.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Istaroxime.Approved, Investigational, Vet Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Istaroxime is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Istaroxime is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Istaroxime.Approved
SaquinavirThe serum concentration of Istaroxime can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Istaroxime can be increased when it is combined with Secoisolariciresinol.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Istaroxime is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Istaroxime.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Istaroxime.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Istaroxime.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Istaroxime can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Istaroxime is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Istaroxime.Investigational
St. John's WortThe serum concentration of Istaroxime can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneIstaroxime may increase the fluid retaining activities of Stanolone.Illicit, Investigational
StanozololIstaroxime may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Istaroxime can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Istaroxime.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Istaroxime.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Istaroxime.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Istaroxime.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Istaroxime can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Istaroxime can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Tacrine.Investigational, Withdrawn
TalniflumateThe risk or severity of adverse effects can be increased when Istaroxime is combined with Talniflumate.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Istaroxime.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Istaroxime is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Istaroxime.Approved, Withdrawn
TelithromycinThe serum concentration of Istaroxime can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Istaroxime.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Istaroxime.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Istaroxime.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Istaroxime.Approved
TestosteroneIstaroxime may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone cypionateIstaroxime may increase the fluid retaining activities of Testosterone cypionate.Approved
Testosterone enanthateIstaroxime may increase the fluid retaining activities of Testosterone enanthate.Approved
Testosterone propionateIstaroxime may increase the fluid retaining activities of Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateIstaroxime may increase the fluid retaining activities of Testosterone undecanoate.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Istaroxime is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Istaroxime.Approved
TiboloneThe serum concentration of Istaroxime can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Istaroxime.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Istaroxime.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Istaroxime.Approved
TorasemideIstaroxime may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Istaroxime.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Istaroxime is combined with Triamcinolone.Approved, Vet Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Istaroxime.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Istaroxime is combined with Trichlorfon.Vet Approved
TrichlormethiazideIstaroxime may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Istaroxime.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Istaroxime.Approved
TromethamineThe bioavailability of Istaroxime can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Tubocurarine.Approved
Typhoid VaccineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Typhoid Vaccine.Approved
TyrothricinThe risk or severity of adverse effects can be increased when Istaroxime is combined with Tyrothricin.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Istaroxime.Approved, Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Istaroxime is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VoriconazoleThe serum concentration of Istaroxime can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinIstaroxime may increase the anticoagulant activities of Warfarin.Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Istaroxime is combined with Yellow Fever Vaccine.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Istaroxime.Approved, Investigational
ZeranolThe serum concentration of Istaroxime can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Istaroxime.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Istaroxime.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
28521583
ChEMBL
CHEMBL2093999
Wikipedia
Istaroxime

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingBasic ScienceCongestive Heart Failure (CHF)1
1RecruitingTreatmentHealthy Volunteers1
1WithdrawnTreatmentHeart Failure, Unspecified1
2CompletedTreatmentHeart Failure, Unspecified1
2RecruitingTreatmentAcute Decompensated Heart Failure (ADHF)1
2WithdrawnTreatmentHeart Failure, Unspecified1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0174 mg/mLALOGPS
logP2.4ALOGPS
logP2.64ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)19.56ChemAxon
pKa (Strongest Basic)8.66ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area81.75 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity99.7 m3·mol-1ChemAxon
Polarizability41.73 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as androstane steroids. These are steroids with a structure based on the 19-carbon androstane skeleton.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Androstane steroids
Direct Parent
Androstane steroids
Alternative Parents
6-oxosteroids / 17-oxosteroids / Oxime ethers / Ketones / Organic oxides / Monoalkylamines / Hydrocarbon derivatives
Substituents
Androstane-skeleton / 17-oxosteroid / Oxosteroid / 6-oxosteroid / Ketone / Oxime ether / Organic oxide / Organic oxygen compound / Amine / Organooxygen compound
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
S100 protein binding
Specific Function
This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol to the sarcoplasmic reticulum lumen. Isoform 2 is involved in the regulati...
Gene Name
ATP2A2
Uniprot ID
P16615
Uniprot Name
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2
Molecular Weight
114755.765 Da
References
  1. Mattera GG, Lo Giudice P, Loi FM, Vanoli E, Gagnol JP, Borsini F, Carminati P: Istaroxime: a new luso-inotropic agent for heart failure. Am J Cardiol. 2007 Jan 22;99(2A):33A-40A. Epub 2006 Sep 18. [PubMed:17239702]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Mattera GG, Lo Giudice P, Loi FM, Vanoli E, Gagnol JP, Borsini F, Carminati P: Istaroxime: a new luso-inotropic agent for heart failure. Am J Cardiol. 2007 Jan 22;99(2A):33A-40A. Epub 2006 Sep 18. [PubMed:17239702]

Drug created on March 19, 2008 10:14 / Updated on July 02, 2018 20:53